English | Español

Bristol-Myers Squibb
Press release submission | Aug 9, 2020

BRISTOL-MYERS SQUIBB: Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma

Press release submission | Feb 16, 2020

BRISTOL-MYERS SQUIBB: Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Carol Ostrow | Dec 27, 2017

Restrictions on Opdivo combination trials for multiple myeloma treatment lifted by FDA
Carol Ostrow | Dec 27, 2017

Seattle Genetics, Bristol-Myers Squibb report Hodgkin treatment study interim results
Carol Ostrow | Dec 26, 2017

Bristol-Myers Squibb, Pfizer, others aim to raise awareness of stroke risk in atrial fibrillation patients
Robert Hadley | Nov 8, 2017

Europe agency approves expanded use of Bristol-Myers Squibb’s Opdivo to treat advanced melanoma
Carol Ostrow | Oct 14, 2017

Opdivo approved for treating certain liver cancer patients
Carol Ostrow | Oct 1, 2017

AbbVie, Bristol-Myers Squibb collaborate on anti-cancer regimen to target lung tumors

Trending
+ Regulatory
Patient Daily | Feb 14, 2025

Spokesperson for Patients Come First: 340B program is ‘one of the most blatant abuses of a governmental program’
+ Pharmaceuticals
Patient Daily | Feb 18, 2025

Expert tips for managing springtime allergies effectively
+ Pharmaceuticals
Patient Daily | Feb 18, 2025

Understanding fainting: A look at potential cardiac implications
+ Pharmaceuticals
Patient Daily | Feb 19, 2025

American Lung Association hosts Fight For Air Climb in Los Angeles